Edition:
United Kingdom

Adamis Pharmaceuticals Corp (ADMP.OQ)

ADMP.OQ on NASDAQ Stock Exchange Capital Market

1.30USD
26 Jun 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.30
Open
$1.28
Day's High
$1.32
Day's Low
$1.26
Volume
44,531
Avg. Vol
61,611
52-wk High
$5.10
52-wk Low
$1.25

Latest Key Developments (Source: Significant Developments)

Adamis Pharmaceuticals Provides Update On Its Higher Dose Naloxone Injection Product
Tuesday, 11 Jun 2019 

June 11 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS PROVIDES UPDATE ON ITS HIGHER DOSE NALOXONE INJECTION PRODUCT.ADAMIS PHARMACEUTICALS - FDA HAS ACKNOWLEDGED RECEIPT OF CO'S AMENDMENT TO PREVIOUSLY SUBMITTED NDA FOR ITS HIGHER DOSE NALOXONE INJECTION PRODUCT.ADAMIS PHARMACEUTICALS - REVISION REMOVED EVZIO AS A REFERENCE LISTED DRUG AND WITHDREW ASSOCIATED PARAGRAPH IV CERTIFICATION.ADAMIS PHARMACEUTICALS - BELIEVES AMENDED NDA WILL NOT BE SUBJECT TO A 30-MONTH STAY.ADAMIS PHARMACEUTICALS - BELIEVES FDA WILL BE FREE TO ISSUE APPROVAL AS SOON AS IT COMPLETES A SATISFACTORY REVIEW OF CO'S NALOXONE NDA.ADAMIS PHARMACEUTICALS CORP - DECIDED TO AMEND ITS ORIGINAL NDA AFTER CONSULTING WITH FDA REGARDING PROPOSED CHANGE.ADAMIS PHARMACEUTICALS - REMOVAL OF PARAGRAPH IV CERTIFICATION DOES NOT TERMINATE PREVIOUSLY ANNOUNCED LAWSUIT FILED BY KALÉO INC.  Full Article

Adamis Pharmaceuticals Q1 Revenue $4.9 Million
Thursday, 9 May 2019 

May 9 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND BUSINESS UPDATE.Q1 REVENUE $4.9 MILLION VERSUS REFINITIV IBES ESTIMATE OF $5.8 MILLION.CASH AND EQUIVALENTS AT END OF Q1 WAS $9.2 MILLION.  Full Article

Adamis Pharmaceuticals Announces 2018 Financial Results And Provides Business Update
Friday, 15 Mar 2019 

March 15 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS ANNOUNCES 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.AT DEC 31 2018, CO HAD CASH AND CASH EQUIVALENTS OF $19.3 MILLION.  Full Article

Adamis Pharmaceuticals Announces FDA Acceptance For Review Of The New Drug Application Of Its Higher Dose Naloxone Injection Product Candidate
Thursday, 14 Mar 2019 

March 14 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF THE NEW DRUG APPLICATION OF ITS HIGHER DOSE NALOXONE INJECTION PRODUCT CANDIDATE.ADAMIS PHARMACEUTICALS CORP - FDA FURTHER PROVIDED A TARGET AGENCY ACTION DATE OF OCTOBER 31, 2019.ADAMIS PHARMACEUTICALS CORP -FDA HAD DETERMINED THAT NDA WAS SUFFICIENTLY COMPLETE TO PERMIT A SUBSTANTIVE REVIEW.  Full Article

Adamis Provides Regulatory Update On Sublingual Tadalafil
Tuesday, 26 Feb 2019 

Feb 26 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PROVIDES REGULATORY UPDATE ON SUBLINGUAL TADALAFIL.ADAMIS PROVIDES REGULATORY UPDATE ON SUBLINGUAL TADALAFIL.FDA REQUESTED CO SUPPLEMENT AND INCLUDE IN RESUBMITTED NDA LONGER REAL-TIME (VERSUS ACCELERATED) STABILITY DATA.ADAMIS PROVIDES REGULATORY UPDATE ON SUBLINGUAL TADALAFIL.ADAMIS PHARMACEUTICALS - RECEIVED A REFUSAL TO FILE LETTER FROM FDA REGARDING ITS NEW DRUG APPLICATION (NDA) FOR ITS SUBLINGUAL TADALAFIL PRODUCT.FDA DETERMINED THAT SUBMITTED NDA WAS NOT SUFFICIENTLY COMPLETE TO PERMIT A SUBSTANTIVE REVIEW.ADAMIS PHARMACEUTICALS- RECEIVED REFUSAL TO FILE LETTER FROM UNITED STATES FDA REGARDING NEW DRUG APPLICATION NDA FOR ITS SUBLINGUAL TADALAFIL PRODUCT.ADAMIS PHARMACEUTICALS - FDA REQUESTED CO SUPPLEMENT & INCLUDE IN RESUBMITTED NDA ADDITIONAL DISSOLUTION DATA FOR BOTH CLINICAL & REGISTRATION BATCHES.MAY SEEK IMMEDIATE GUIDANCE FROM FDA, INCLUDING REQUESTING A TYPE A MEETING, TO DISCUSS LETTER.  Full Article

Adamis Pharmaceuticals’ Commercial Partner Launches Symjepi (Epinephrine) In The US
Wednesday, 16 Jan 2019 

Jan 16 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS’ COMMERCIAL PARTNER LAUNCHES SYMJEPI™ (EPINEPHRINE) IN THE US.ADAMIS PHARMACEUTICALS CORP - WORKING CLOSELY WITH SANDOZ TO PREPARE FOR US LAUNCH OF SYMJEPI 0.15 MG INJECTION.ADAMIS PHARMACEUTICALS - SYMJEPI WILL BE ROLLED OUT VIA A PHASED LAUNCH AND WILL INITIALLY BE AVAILABLE IN INSTITUTIONAL SETTING.  Full Article

Adamis Pharmaceuticals Provides Update On Symjepi's U.S. Launch
Thursday, 6 Dec 2018 

Dec 6 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS PROVIDES UPDATE ON THE U.S. LAUNCH OF SYMJEPI.ADAMIS PHARMACEUTICALS - PROVIDED BUSINESS UPDATE ANNOUNCING U.S. LAUNCH OF FDA-APPROVED SYMJEPI 0.3MG INJECTION IS PLANNED FOR EARLY Q1 2019..ADAMIS PHARMACEUTICALS - MANUFACTURE OF COMMERCIAL BATCHES COMPLETED, ADAMIS WILL BEGIN SHIPPING TO SANDOZ DISTRIBUTION CENTERS DURING DEC.  Full Article

Adamis Pharmaceuticals Reports Q3 Revenue Of $3.8 Million
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE.Q3 REVENUE $3.8 MILLION.Q3 REVENUE VIEW $5.2 MILLION -- THOMSON REUTERS I/B/E/S.AT SEPTEMBER 30, 2018, COMPANY HAD CASH AND CASH EQUIVALENTS OF $32.0 MILLION.EXPECTS THAT RESEARCH AND DEVELOPMENT SPENDING IN Q4 OF 2018 WILL SEE AN INCREASE.  Full Article

Adamis Pharmaceuticals Receives FDA Approval For Its Lower Dose Symjepi Product
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS RECEIVES FDA APPROVAL FOR ITS LOWER DOSE SYMJEPI PRODUCT.  Full Article

Adamis Pharmaceuticals Says Working With Sandoz To Prepare Symjepi Launch
Monday, 27 Aug 2018 

Aug 27 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS PROVIDES BUSINESS UPDATE.ADAMIS PHARMACEUTICALS - WORKING CLOSELY WITH SANDOZ TO PREPARE A SUCCESSFUL LAUNCH FOR SYMJEPI.ADAMIS PHARMACEUTICALS - FDA PROVIDED PDUFA DATE OF SEPT 27, 2018 FOR LOW DOSE SYMJEPI PRODUCT CANDIDATE.ADAMIS PHARMACEUTICALS - LOW DOSE SYMJEPI PRODUCT CANDIDATE IS STILL UNDER REVIEW WITH U.S. FDA.  Full Article